Table 4.
Laboratory biomarkers of COVID-19 patients according to the presence or absence of post-COVID dyspnea at 6- and 12-month follow-ups
| Post-COVID dyspnea (n = 71) | No post-COVID dyspnea (n = 341) | p value | |
|---|---|---|---|
| 6-month follow-up period | |||
| Hemoglobin, g/dL | 14.0 (1.35) | 14.0 (1.6) | 0.896 |
| Lymphocyte, ×109/L | 1.11 (0.45) | 1.09 (0.4) | 0.598 |
| Neutrophils, ×109/L | 4.8 (2.5) | 5.3 (2.75) | 0.184 |
| NLR | 4.2 (4.1) | 4.85 (4.5) | 0.350 |
| Platelets,* ×109/L | 141.8 (73.2) | 453.7 (102.4) | 0.001* |
| Glucose, mg/mL | 125.5 (50.5) | 118.5 (30.8) | 0.208 |
| CK, mg/L | 96.4 (34.0) | 105.0 (43.0) | 0.209 |
| ALT,* U/L | 38.5 (22.4) | 51.0 (40.5) | 0.017* |
| AST,* U/L | 39.0 (20.7) | 50.0 (34.0) | 0.012* |
| LDH,* U/L | 245.0 (60.5) | 287.7 (98.5) | 0.003* |
| CRP, mg/L | 70.0 (67.0) | 85.0 (88.5) | 0.185 |
| D-dimer, ng/mL | 928.5 (849.2) | 974.1 (946.4) | 0.601 |
|
| |||
| Post-COVID dyspnea (n = 56) | No post-COVID dyspnea (n = 356) | p value | |
|
| |||
| 12-month follow-up period | |||
| Hemoglobin, g/dL | 13.5 (1.7) | 14.0 (1.5) | 0.475 |
| Lymphocyte, ×109/L | 1.15 (0.55) | 1.08 (0.4) | 0.402 |
| Neutrophils, ×109/L | 5.73 (3.0) | 5.25 (2.6) | 0.329 |
| NLR | 5.1 (3.9) | 4.8 (4.5) | 0.586 |
| Platelets,* ×109/L | 214.1 (74.25) | 466.25 (92.8) | 0.009* |
| Glucose, mg/mL | 117.0 (25.7) | 119.5 (36.3) | 0.649 |
| CK, mg/L | 98.0 (41.1) | 105.2 (42.0) | 0.375 |
| ALT,* U/L | 38.9 (22.9) | 48.8 (35.1) | 0.025* |
| AST,* U/L | 36.7 (16.2) | 48.1 (29.2) | 0.035* |
| LDH,* U/L | 254.8 (75.8) | 279.1 (96.5) | 0.02* |
| CRP, mg/L | 85.3 (90.7) | 91.4 (86.0) | 0.717 |
| D-dimer, ng/mL | 916.9 (758.7) | 961.1 (882.9) | 0.545 |
n, number; SD, standard deviation. * Statistically significant differences between groups (p < 0.05).